CXCL9 and breast cancer: Therefore, the targeting of SRC-3 by SI-2 and SRC-3 KD recruits Cxcr3-expressing cytotoxic immune cells, such as CD4 + , CD8 + , and CD56 + (NK cells), into breast cancers by increasing Cxcl9 and then generates an antitumor immune microenvironment to suppress breast cancer progression (Fig. 11) [36, 37].